Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
The U.K. government backs six projects aimed to fight the coronavirus outbreak, promising $23 million (£20 million) in funding. The projects, including two focused on vaccination trials, will help fast track the development of a vaccine to stop the spread of the coronavirus, leading to the death of more than 16,500 people across the globe.
As the world reels from the devastating impact and the looming threat of the novel coronavirus COVID-19, researchers around the globe are racing to find a cure that will reduce symptom severity and reverse the course of the disease, freeing up more hospital space and making it possible to treat more of the severely affected cases.
Researchers from the University of Oxford have launched a new clinical trial to test the effects of potential drug treatments for patients admitted to hospital with COVID-19. The first patients have now been recruited.
Researchers from China and the United Kingdom have collaborated to conduct a clinical trial looking at the efficacy of a combination of two anti-HIV drugs lopinavir and ritonavir to combat severe cases of COVID-19. Their study titled, “A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19,” was published in the latest issue of the New England Journal of Medicine (NEJM).
The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus, which hit China with the disease now named COVID-19 in December 2019 and has since spread to over 70 countries, has caused over 90,000 cases, and 3,117 fatalities, with 95% or more of both being in China.
As the scientific community scrambles to find a drug that can effectively treat tens of thousands of patients sickened by a new respiratory virus, they are trying some surprising remedies: medicines targeting known killers like HIV, Ebola and malaria.
Researchers from the University of North Carolina at Chapel Hill have developed a unique new multi-drug delivery system that could p-rove to be useful for persons who need to take several drugs in a day as part of a regimen.
Like that famous bowl of porridge, when leptin levels are "just right" they help protect our cardiovascular health, scientists say.
The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.
New guidelines for Canada have been published in the Canadian Medical Association Journal online this week that outline the use of new anti-HIV medications among high risk populations who are at risk of contracting HIV from getting the dreaded infection. These new guidelines aim to provide the clinicians with resources and support he added.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.
The non-profit research and development organization Drugs for Neglected Diseases initiative has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.
Antiretroviral drugs have been life-changing therapies for HIV patients, but they can have significant side effects.
A study conducted by Canadian and Australian researchers shows that nearly everywhere in Canada, the provinces and territories impose obstacles to reimbursement of new direct-acting antivirals (DAA) to treat hepatitis C by because of their cost.
It probably isn't surprising to read that pharmaceutical drugs don't always do what they're supposed to. Adverse side effects are a well-known phenomenon and something many of us will have experienced when taking medicines.
AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.
Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).
The Medicines Patent Pool today announced a new licensing agreement with AbbVie, a global biopharmaceutical company, that seeks to address future demands for HIV treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa. The agreement has been reached in particular to help ensure sustainability of long-term supply of LPV/r, the most widely used second-line HIV treatment in South Africa and across Africa.